Compare 10X Genomics Inc (TXG) vs Texas Instruments Incorporated (TXN) Price & Performance

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.

Texas Instruments (TXN) trades at $288.20, down 0.26% on the day, with strong technical momentum showing bullish moving averages and key support at $284. The company demonstrates robust fundamentals with 31.11% net margins and 34.97% ROE, though valuation ratios remain elevated with a P/E of 43.8. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss, while data center sales growth and dividend payments highlight ongoing shareholder returns.

Outlook remains positive with analyst consensus targeting $325 (13% upside) amid accelerating revenue growth and AI-driven demand. Key risks include premium valuation sensitivity, cyclical semiconductor exposure, and rising debt levels. Institutional sentiment is bullish with 48% buy ratings, supported by strong cash flow generation and strategic positioning in industrial and data center markets.